Baird raised the firm’s price target on Sarepta (SRPT) to $22 from $15 and keeps a Neutral rating on the shares. The firm updated its model following the release of its 3-year EMBARK data which showed encouraging slowing of disease progression.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Therapeutics: Safety Uncertainty and Label Risk Overshadow Elevidys Data, Supporting Sell/High Risk Rating
- H.C. Wainwright reiterates Sell on Sarepta after 3-year data
- Midday Fly By: Minnesota CEOs call for deescalation, Nvidia invests in CoreWeave
- Sarepta rises 14.1%
- Morning Movers: USA Rare Earth surges after government funding pact